Moderna Inc. claimed that its Omicron-focused COVID-19 vaccines had improved immune responses against BA.4 and BA.5 sub-variants of Omicron, found Moderna’s latest study. Data suggests that in adults who had been vaccinated and received booster shots, both of Moderna’s Omicron-focused vaccines, including mRNA-1273.214 and mRNA-1273.222, has produced high antibody response against BA.4 and BA.5 sub-variants than company’s original COVID-19 vaccine.
In a study of around 40 volunteers, Moderna claimed that levels of neutralising antibody response has been dropped by 5-fold against the emerging Omicron sub-variant BQ.1.1 compared with BA.4 and BA.5, even though the neutralising activity of the virus still remained robust.
Omicron-focused COVID-19 vaccine shots developed by both Pfizer and Modern have already received approval from the US FDA for both adults and children above five years based on the data from the pre-clinical studies.
Prizer and BioNTech has also reported that their Omicron-focused COVID-19 vaccine shot that targets Omicron BA.4 and BA.5 sub-variants, have produced strong antibody response in older adults than the original vaccine shot.
Until now, around 31.4 million people in the United States had received the updated COVID-19 vaccine, with around 5.1 million receiving it in last week, according to the statistics from the US government.
